Forbion Capital Partners is the famous VC, which was founded in 2007. The company was established in Europe in The Netherlands. The leading representative office of defined VC is situated in the Naarden.
The fund has specific favorite in a number of founders of portfolio startups. If startup sums 3 or 4 of the founder, the chance for it to be financed is low. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline AM Pharma, Mitralign, BioVex Among the most popular fund investment industries, there are Clinical Trials, Health Diagnostics. For fund there is no match between the location of its establishment and the land of its numerous investments - United States.
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Forbion Capital Partners, startups are often financed by Oxford Bioscience Partners, Giza Venture Capital, ABN AMRO Fund. The meaningful sponsors for the fund in investment in the same round are Oxford Bioscience Partners, New Science Ventures, Andera Partners. In the next rounds fund is usually obtained by Takeda Ventures, Oxford Bioscience Partners, NGN Capital.
The higher amount of exits for fund were in 2015. Speaking about the real fund results, this VC is 14 percentage points more often commits exit comparing to other organizations. The fund is constantly included in 2-6 investment rounds annually. Opposing the other organizations, this Forbion Capital Partners works on 10 percentage points more the average amount of lead investments. The average startup value when the investment from Forbion Capital Partners is 50-100 millions dollars. Deals in the range of 10 - 50 millions dollars are the general things for fund. The important activity for fund was in 2011. Despite it in 2019 the fund had an activity.
Besides them, we counted 10 critical employees of this fund in our database.
Related Funds
Funds with similar focus
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Purespring Therapeutics | 09 Oct 2024 | London, England, United Kingdom | |||
LOQUS23 THERAPEUTICS | 02 Oct 2024 | London, England, United Kingdom | |||
NOVAMEAT | $20M | 12 Sep 2024 | Barcelona, Catalonia, Spain | ||
Solasta Bio | $14M | 11 Sep 2024 | Glasgow City, Glasgow, United Kingdom | ||
Navigator Medicines | $100M | 27 Aug 2024 | Scotch Plains, New Jersey, United States | ||
AIRNA | $60M | 31 Jul 2024 | Cambridge, Massachusetts, United States | ||
Marea Therapeutics | $190M | 18 Jun 2024 | San Francisco, California, United States | ||
Beacon Therapeutics | $170M | 03 Jun 2024 | London, England, United Kingdom | ||
Pheon Therapeutics | $120M | 21 May 2024 | London, England, United Kingdom |
– VectorY Therapeutics announced the completion of a €31m seed financing round.
– The oversubscribed round was co-led by founding investor Forbion and a leading global investment firm. BGV and Eli Lilly and Company also joined the syndicate.
– The proceeds from this seed financing will be used by the Company to establish pre-clinical proof of concept for vectorized antibodies in target indications of ALS and Alzheimer’s.
– The Company will also use the funds to establish proprietary manufacturing capabilities, including a state-of-the-art GMP facility in the Netherlands.
– The Company also announced the appointment of a new Chief Executive Officer, Alexander Vos, and Chief Technology Officer Dr. Sander van Deventer, both highly experienced pioneers in the cell and gene therapy field.
– Numab Therapeutics AG, a clinical stage biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer and inflammation, announced the closing of a CHF 100 million (approximately USD 110 million) Series C financing.
– The financing was co-led by new investors Novo Holdings and HBM Partners, with participation from additional new investors Forbion via its Forbion Growth Opportunities Fund, Cormorant Asset Management, BVF Partners L.P., RTW Investments L.P., funds and accounts under the management of BlackRock, Octagon Capital Advisors, and existing investors.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Purespring Therapeutics | 09 Oct 2024 | London, England, United Kingdom | |||
LOQUS23 THERAPEUTICS | 02 Oct 2024 | London, England, United Kingdom | |||
NOVAMEAT | $20M | 12 Sep 2024 | Barcelona, Catalonia, Spain | ||
Solasta Bio | $14M | 11 Sep 2024 | Glasgow City, Glasgow, United Kingdom | ||
Navigator Medicines | $100M | 27 Aug 2024 | Scotch Plains, New Jersey, United States | ||
AIRNA | $60M | 31 Jul 2024 | Cambridge, Massachusetts, United States | ||
Marea Therapeutics | $190M | 18 Jun 2024 | San Francisco, California, United States | ||
Beacon Therapeutics | $170M | 03 Jun 2024 | London, England, United Kingdom | ||
Pheon Therapeutics | $120M | 21 May 2024 | London, England, United Kingdom |